PCOS, a condition impacting millions of women worldwide, gets a new name

PCOS, a condition impacting millions of women worldwide, gets a new name

PCOS a condition impacting millions of women – For decades, a condition that affects women’s fertility and increases their risk of diabetes has often gone unnoticed, but experts are now pushing for a rebranding effort to ensure more people receive the care they need. Polycystic ovarian syndrome (PCOS), long the accepted term, may soon be replaced by a more comprehensive name: polyendocrine metabolic ovarian syndrome (PMOS). This shift aims to highlight the condition’s broader health implications, which extend far beyond the ovaries.

The Evolution of Understanding

PCOS, as its name implies, was historically associated with ovarian cysts. However, the reality is far more complex. According to the World Health Organization (WHO), the condition can manifest in a wide array of symptoms, including irregular menstrual cycles, difficulty conceiving, androgenic hair loss, and a heightened risk for type 2 diabetes and cardiovascular disease. The term “PCOS” has long been a source of confusion, leading many to underestimate its severity or misdiagnose it altogether.

Dr. Helena Teede, an endocrinologist and professor of Women’s Health at Monash University in Australia, has spent over 25 years combating misconceptions about the condition. “People used to think PCOS was just about cysts on the ovaries,” she explained. “That narrow perception caused missed diagnoses and treatments that didn’t address the full scope of the problem.” Teede, who spearheaded the effort to rename the condition, is the lead author of a new paper published in the Lancet that outlines the rationale for this change.

The Path to a New Identity

The journey to update the name took nearly 14 years and involved collaboration among 56 patient advocacy groups and medical professionals worldwide. The revised name, PMOS, is intended to reflect the condition’s role as a metabolic disorder. “The term ‘polycystic ovary’ creates a false impression,” said Dr. Alla Vash-Margita, an associate professor at Yale University and division chief for pediatric adolescent gynecology. “It suggests the problem is localized to the ovaries, but the reality is much broader. The name needs to capture the systemic nature of the condition.”

Dr. Andrea Dunaif, a professor at the Icahn School of Medicine at Mount Sinai, highlighted how the understanding of the syndrome has evolved over time. Initially viewed as a reproductive issue, PCOS was later linked to hormonal imbalances, such as elevated male hormone levels, which can disrupt menstrual regularity and fertility. In the 1980s, researchers discovered its connection to insulin resistance, a condition where the body struggles to respond to insulin. “This means the body must produce more insulin to maintain normal function,” Dunaif noted. “When this process fails, diabetes can develop.”

As research advanced, the condition’s reach expanded to include risks for liver and heart disease, as well as more recent associations with sleep apnea, depression, anxiety, and body dysmorphia. These findings underscore the need for a name that accurately represents the syndrome’s multifaceted impact. “PCOS was never a perfect label,” Teede said. “The new name emphasizes the endocrine and metabolic aspects that are central to its complexity.”

Stigma and Misconceptions

Historically, the stigma surrounding PCOS has been significant. The name has often been linked to stereotypes, with some people assuming individuals with the condition have visible ovarian cysts. “The term ‘polycystic’ gave the wrong impression,” Vash-Margita added. “People believed the condition was about large cysts, but many patients have no such visible signs.” This misunderstanding has contributed to delays in diagnosis and treatment, as well as a lack of recognition for the condition’s broader effects.

One of the primary goals of the name change is to shift public perception and ensure the syndrome is treated as a serious, lifelong health issue. Rachel Morman, Chair of Verity PCOS UK, expressed optimism about the new terminology in a news release. “This shift will reframe the conversation and demand that PMOS is viewed as the complex condition it truly is,” she said. The hope is that a more precise name will encourage greater awareness, prompting both patients and healthcare providers to take the syndrome more seriously.

Collaboration and Global Effort

The renaming of the syndrome is the result of extensive global collaboration. The Lancet paper, which formalizes the change, reflects input from 56 organizations dedicated to addressing women’s health. This collective effort highlights the need for a unified approach to diagnosis and treatment, as the condition affects multiple systems within the body. “PCOS was a label that didn’t fully align with the syndrome’s true nature,” Teede said. “By adopting PMOS, we acknowledge the endocrine and metabolic roles that drive its symptoms.”

Dunaif acknowledged that while the new name is a step forward, it may still require further refinement. She suggested that subtypes could be useful to distinguish between individuals experiencing primarily reproductive issues and those facing metabolic challenges. “The name PMOS is more accurate than PCOS,” she said, “but it might benefit from additional categories to better tailor treatment strategies.”

Broader Implications for Health

The rebranding also aims to integrate PMOS into a wider framework of metabolic health. As research continues to uncover its connections to conditions like early dementia, the importance of addressing the syndrome becomes even more apparent. “Metabolic syndrome is a major risk factor for cognitive decline,” one study suggests. “What you do in the early stages can make a significant difference.”

Teede emphasized that the new name is not just a linguistic update but a call to action for medical professionals across specialties. “Gynecologists have done a good job of recognizing the condition,” she said. “However, PMOS’s impact on the endocrine system and metabolism means that other fields—such as endocrinology, cardiology, and psychiatry—must also become more involved in its management.”

The renaming of PCOS to PMOS represents a pivotal moment in the medical community’s understanding of the syndrome. By shedding the outdated label, experts hope to foster a more accurate and inclusive dialogue about its effects, ultimately improving patient outcomes. As the condition continues to be studied, the new name may pave the way for advancements in treatment and research, ensuring that women affected by PMOS receive the comprehensive care they deserve.